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Trauma is a serious global health problem, accounting for approximately one in 10 deaths
worldwide. Uncontrollable bleeding accounts for 39% of trauma-related deaths and is the leading
cause of potentially preventable death in patients with major trauma. While bleeding from
vascular injury can usually be repaired surgically, coagulopathy-related bleeding is often more
difficult to manage and may also mask the site of vascular injury. The causes of coagulopathy in
patients with severe trauma are multifactorial, including consumption and dilution of platelets and
coagulation factors, as well as dysfunction of platelets and the coagulation system. The interplay
between hypothermia, acidosis and progressive coagulopathy, referred to as the ‘lethal triad’,
often results in exsanguination. Current management of coagulopathy-related bleeding is based
on blood component replacement therapy. However, there is a limit on the level of haemostasis
that can be restored by replacement therapy. In addition, there is evidence that transfusion of red
blood cells immediately after injury increases the incidence of post-injury infection and multiple
organ failure. Strategies to prevent significant coagulopathy and to control critical bleeding
effectively in the presence of coagulopathy may decrease the requirement for blood transfusion,
thereby improving clinical outcome of patients with major trauma.
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Trauma is a serious global health problem, accounting for
approximately one in 10 deaths worldwide.75 78 Trauma
accounts for 5 million deaths per year, of which 1 million
are in Europe.78 It is estimated that by 2010 the annual
trauma-related mortality worldwide will increase to
8.4 million.74 Almost 50% of injury-related mortality is
in young people between the ages of 15 and 44 yr.78
Hence, the burden to society due to loss of productivity is
enormous, amounting to a total of 182 million disability-
adjusted life years lost annually.78
Resuscitation of trauma patients has improved signifi-
cantly over the years. However, uncontrolled bleeding
remains a major challenge, accounting for around 40% of
trauma-related deaths,46 47 91 and uncontrollable bleeding is
the leading cause of potentially preventable and early in-
hospital death.46 91 Hence, effective control of bleeding may
decrease mortality.
Life-threatening bleeding in trauma patients is usually cau-
sed by a combination of vascular injury and coagulopathy.
Injury to major vessels often requires surgical intervention,
but arterial embolization can be a useful approach to bleeding
control, even in patients with multiple trauma.35 76 Coagu-
lopathy-related diffuse bleeding is difficult to manage. The
causes of coagulopathy are multifactorial and interrelated,
including consumption and dilution of coagulation factors
and platelets, dysfunction of platelets and the coagulation
system, increased fibrinolysis, compromise of the coagula-
tion system by the infusion of colloid, hypocalcaemia,
and disseminated intravascular coagulation-like syn-
drome.29 30 36 52 71 86 87 Coagulopathy in conjunction with
hypothermia and acidosis is often referred to as the ‘lethal
triad’ because of the high mortality.36 48 58
Resuscitation of trauma patients with critical bleeding
involves the infusion of large volumes of crystalloid and col-
loid followed by red blood cell (RBC) transfusion. However,
RBC concentrates contain negligible amounts of platelets
and coagulation factors. As a result, RBC transfusion, while
improving oxygen transport, does not correct depletion of
coagulation factors and platelets and can result in coagulo-
pathy. Current management for coagulopathy-related
bleeding is mainly based on transfusion of fresh frozen
plasma (FFP), platelets, coagulation factor concentrates
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(fibrinogen and prothrombin complex concentrates) and,
where available, cryoprecipitate. When coagulopathy is
accompanied by hypothermia and acidosis, even adequate
replacement may not be able to control the bleeding, res-
ulting in exsanguination.28 Coagulopathy occurs early in the
post-injury period,61 and has been shown to be an independ-
ent predictor of mortality.55 60 61 Therefore, correction of
coagulopathy may potentially decrease mortality in patients
with severe trauma.
Infection and multiple organ failure (MOF) are
serious complications in patients who survive the initial
insult from injury. Evidence has been accumulating
that RBC transfusion may have negative effects on long-
term outcome by increasing the incidence of post-injury
infection and MOF.15 22 73 92 107 A reduction in RBC trans-
fusion may decrease these complications and improve
outcome.
This article discusses the pathophysiology of coagulo-
pathy in major trauma, the interrelationship between mas-
sive RBC transfusion and coagulation, unresolved issues in
blood component replacement therapy, and the effect of
allogeneic RBCs on outcome. In addition, it provides
some guidance for the therapeutic use of blood components.
Finally, the unmet need for effective haemostatic therapy is
highlighted.
Pathophysiology of coagulopathy in trauma
Haemostasis process
Haemostatic response to vascular injury consists of a series
of interactions between the subendothelial matrix, platelets
and coagulation proteins12 44 45 56 103 (Fig. 1). Normally,
the endothelial cells lining the inner wall of blood vessels
prevent the subendothelial matrix and tissue factor from
coming into direct contact with circulating platelets and
coagulation proteins. Vascular injury disrupts the integrity
of the endothelial lining, exposing the subendothelial mat-
rix. The adherence of platelets to the subendothelial matrix
leads to platelet activation and platelet plug formation. The
platelet plug acts as a catalytic surface for the recruitment
and activation of coagulation proteins, optimizing the
coagulation process.
The coagulation process (Fig. 2) is initiated by the binding
of activated factor VII (which normally circulates in minute
quantities) to the exposed tissue factor, which initiates
coagulation by activating factors IX and X. Activated fac-
tor IX also activates factor X. Activated factor X, in turn,
rapidly converts prothrombin to thrombin, generating small
amounts of thrombin which are insufficient to convert fib-
rinogen to fibrin. The generation of thrombin is amplified by
several feedback mechanisms. First, the generation of acti-
vated factor VII is increased by activation of factor VII
bound to tissue factor by activated factors VII, IX and X.
Second, the thrombin generated activates factors V and VIII,
the cofactors which accelerate the activation of prothrombin
and factor X, respectively. Thrombin increases the genera-
tion of activated factor IX by converting factor XI to an
activated form. The generation of large amounts of activated
factor X by activated factors IX and FVIII ensures that suf-
ficient amounts of thrombin are continuously generated to
convert fibrinogen to fibrin, hence forming a clot. In the final
step of coagulation, thrombin activates factor XIII to acti-
vated factor XIII, which then cross-links the soluble fibrin
monomers to form a stable fibrin clot. In addition, thrombin
activates the thrombin-activatable-fibrinolysis inhibitor which
protects the clot from premature fibrinolysis.12 44 45 56 88 103
The haemostatic system is regulated by several antico-
agulant proteins and inhibitors, as well as by the fibrinolytic
process. When operating in balance, these interdependent
processes ensure that the formed fibrin clot stops the bleed-
ing, and subsequently revascularization occurs to maintain
the blood flow. Massive bleeding in patients with major
trauma can stretch the capacity of the coagulation process
to the limit, resulting in coagulopathy, uncontrollable bleed-
ing and exsanguination, even in patients with previously
normal haemostasis.
Consumption coagulopathy
The pathogenesis of coagulopathy in trauma patients is com-
plex. The precise cause is difficult to identify and is likely to
be multifactorial (Table 1). Tissue damage, anoxia and
shock activate the coagulation system, which in turn acti-
vates fibrinolysis.29 30 36 52 87 The occurrence of multiple
intravascular thrombi associated with areas of focal necrosis
in various vital organs is similar to the findings in patients
with disseminated intravascular coagulation.36 Whether
these changes represent a true disseminated intravascular
coagulation remains unclear.65 However, normal activation
of the coagulation and fibrinolytic systems results in
the consumption of platelets and coagulation factors, and
Vascular injury
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Fig 1 Simplified diagram showing the key steps of the haemostasis
process.
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continuing bleeding causes further depletion of these hae-
mostatic constituents from the circulation.
Increased fibrinolysis
Laboratory evidence has demonstrated both hypofibrinolytic
and hyperfibrinolytic states in trauma patients.23 24 87 The
fibrinolytic status of trauma patients will vary with the sever-
ity of injury and the time from injury to the assessment of
fibrinolytic activity. Simmons and colleagues have shown
that immediately following trauma fibrinolytic activity
increases. It returns to normal after the first 24 h in patients
with mild to moderate injury, but remains elevated in those
with major injuries.97 In the presence of hypothermia, fib-
rinolytic activity is increased.106 However, it should be
noted that studies showing increased fibrinolysis in trauma
patients were mainly published before 1990. It is conceiv-
able that advances in emergency care, changes in fluid resus-
citation policy, and improved quality of blood components
might produce different results if such studies were per-
formed today.
Hypothermia-induced coagulopathy
In trauma patients without pre-existing disease or
massive head injury, the following conditions have been
identified as significant risk factors for life-threatening
coagulopathy: injury severity score >25, systolic blood pres-
sure <70 mmHg, acidosis with pH <7.10 and hypothermia
with a body temperature <34C.16 The interrelationship
between hypothermia, metabolic acidosis and progressive
coagulopathy is referred to as the ‘lethal triad’; each factor
exacerbates the others, leading to life-threatening bleeding
or exsanguination (Fig. 3).16 28 48 58 72 The causes of hypo-
thermia are multifactorial and interdependent, including
altered central thermoregulation, decreased heat production
due to tissue hypoperfusion in haemorrhagic shock, expos-
ure to low ambient temperature, and infusion of inadequa-
tely warmed resuscitation fluids and blood components.79
The coagulation process consists of multiple enzymatic
reactions, which are temperature-dependent and function
optimally at 37C. The deleterious effect of hypothermia
on coagulopathy in trauma patients has been well docu-
mented,28 54 77 104 and when occurring in conjunction with
metabolic acidosis, can result in a mortality rate as high as
90%.28 54 The effect of hypothermia on coagulopathy is
difficult to identify by routine coagulation screening tests,
such as prothrombin time (PT) and activated partial throm-
boplastin time (aPTT), because these tests are routinely
carried out at 37C. Nevertheless, when PT and aPTT
tests are carried out at low temperatures, as seen in hypo-
thermic patients, both are significantly prolonged.34 90 105 In
addition, both in vitro and in vivo studies have shown that
hypothermia significantly impairs platelet function and the
formation of a platelet plug70 100 104 105 and activates
fibrinolysis.106
In summary, hypothermia impairs thrombin generation69
and the formation of platelet plugs and fibrin clots, and at the
same time increases clot lysis, resulting in coagulopathy and
uncontrollable bleeding. Routine coagulation tests usually
underestimate the degree of coagulopathy in a hypothermic
patient and this should be taken into consideration when
interpreting the results and correcting the coagulopathy.
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Fig 2 The coagulation process. For explanation see text.
Table 1 The major causes of coagulopathy in trauma patients
Blood loss
Consumption of platelets and coagulation factors
Dilution of coagulation factors and platelets
Increased fibrinolysis
Impaired functions of platelets and coagulation factors
Coagulation-compromising effect of colloids
Hypothermia
Hypocalcaemia
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Decreased levels of coagulation factors
and platelets
Infusion of large volumes of crystalloid and colloid during
resuscitation reduces the concentrations of platelets and
coagulation factors. In addition, thrombocytopenia is seen
commonly in patients who have received massive blood
transfusion, and has been thought to be a major cause of
coagulopathy.14 17 71 86 97 Although platelets are present in
whole blood, storage at 4C severely damages them and
the remaining platelets disappear from the circulation almost
immediatelyafter transfusion.8 71 Incurrent practice, RBCs in
additive solution rather than whole blood are widely used.27
Consequently, RBC units contain negligible amounts of
coagulation factors and platelets, and thrombocytopenia
and subnormal levels of coagulation factors often occur at
an early stage during massive RBC transfusion.
The effect of acute RBC loss on coagulation
The specific effect of RBCs on coagulation is unclear. In
vitro experiments have shown that RBC membranes contain
the enzyme elastase, which can activate factor IX and may
serve as a triggering mechanism for blood coagulation.50 51
In normal volunteers, an acute reduction in haematocrit
results in reversible platelet dysfunction.99 In contrast,
using thromboelastography, Iselin and colleagues have
found that an isolated reduction in haematocrit does not
compromise coagulation.49 As no data from trauma patients
are available, the effect of acute RBC loss on coagulation in
this group of patients is unknown.
Effect of massive RBC transfusion on
coagulation
Blood transfusion in the past was largely dependent on the
use of whole blood, whereas modern practice is based on
the concept of specific component therapy. In developed
countries, most whole blood units are separated within
18–24 h into RBCs, platelets and plasma, and, in some blood
centres, cryoprecipitate is prepared after thawing FFP at
2–4C. Blood component therapy optimizes the use of
resources by allowing components to be used in different
patients. It avoids the potentially harmful effects caused by
the transfusion of surplus constituents.4 For example, trans-
fusion of whole blood instead of RBCs in additive solution to
an anaemic patient increases the risk of plasma-associated
transfusion reactions such as TRALI (transfusion-related
acute lung injury), which is related to the presence of anti-
bodies to HLA or leucocytes in the donor’s plasma.84
While specific component therapy provides both logistic
and economic benefits,4 in massive RBC transfusion, coagu-
lopathy due to low levels of platelets and clotting factors
occurs at an earlier stage compared with the use of whole
blood. A unit of whole blood contains approximately 200 ml
of plasma with sufficient amounts of stable clotting factors,
especially fibrinogen. In contrast, only a negligible amount
of plasma—and therefore coagulation factors and
platelets—remains in an RBC unit, and a plasma-free addit-
ive solution is added to the unit to provide nutrients and
energy to RBCs, as well as pH buffering during storage.2 4
During the Vietnam war, when stored whole blood was used,
it was found that the platelet count did not fall below
100·109 litre1 even after transfusion of 6 litres.97 Now-
adays, in contrast, 85% of patients receiving at least 10 units
of RBCs in additive solution develop thrombocytopenia.27
The relationships between volume of blood loss, replace-
ment volume and the reduction in coagulation factor and
platelet levels are difficult to establish. This is due to several
factors including the dynamics of blood loss, the difficulties
in estimating true blood loss, the interindividual variations
in clotting factor levels and the functionality of organ
systems involved in haemostasis, i.e. the liver, spleen,
and bone marrow. Martinowitz and colleagues found that
in 36 patients with severe trauma, after massive RBC trans-
fusion with a median of 21 units, the median fibrinogen level
Dilution of
coagulation factors
and platelets
Tissue
hypoxia
Acidosis
Colloid and
crystalloid infusion
BleedingSevere trauma
Coagulopathy
Massive RBC
transfusion
Hypothermia
Fig 3 The interplay between metabolic acidosis, hypothermia and progressive coagulopathy in trauma (modified from reference 72, with permission from
Excerpta Medica Inc.).
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was 1.5 g litre1 (interquartile range 1.1–2.6 g litre1).66
A similar finding was reported by Hiippala and colleagues,
who found fibrinogen levels <1.0 g litre1 after replacement
of approximately 1.5 blood volumes in 60 major surgery
patients.42 However, McLoughlin and colleagues found that
fibrinogen levels below 1.0 g litre1 occurred after replace-
ment of only 0.5 blood volume.68 Nevertheless, this study
was carried out in eight patients who had unusually low
baseline levels of fibrinogen (around 1.6 g litre1).
In principle, the timely measurement of haemostatic com-
petence should provide guidance for the management of indi-
vidual patients. Unfortunately, the commonly used tests, PT
and aPTT, are global tests which were originally developed
to monitor anticoagulant therapy and their predictive value
in trauma or surgical settings has never been validated.21
Repeated measurement of fibrinogen concentration can help
determine when fibrinogen replacement therapy is required
in an individual patient. Thromboelastograph data provide
a qualitative and dynamic assessment of coagulation process
from clot formation to clot lysis and use of the
Thromboelastograph may be useful in trauma patients.18
The increased acid load from RBC units may also con-
tribute to coagulopathy. The pH of an RBC unit is low, and
decreases progressively during storage, due to the produc-
tion of lactic acid by RBCs, from around 7.0 initially to
around 6.3 at the end of its shelf-life.53 Because of the
high buffering capacity of plasma in the circulation, trans-
fusion of RBCs with such low pH does not usually cause
acid–base disturbance. However, in the case of trauma
patients who are already acidotic, massive transfusion of
RBCs further increases the acid load,7 which may in turn
exacerbate the ongoing coagulopathy.
RBC transfusion is certainly life-saving in trauma patients
with haemorrhagic shock. However, with the modern RBC
components, which do not contain platelets and coagulation
factors, coagulopathy occurs at an early stage during mas-
sive RBC transfusion.
Excess amounts of citrate anticoagulant are present in
FFP. Trauma patients, particularly those with hypovolaemic
shock or hypothermia, who have received large volumes of
FFP may develop hypocalcaemia through citrate binding to
circulating ionized calcium.3 19 81 Because ionized calcium
is one of the essential elements in coagulation, hypocal-
caemia may contribute to coagulopathy.
Unresolved issues regarding blood
transfusion in trauma
Optimal replacement therapy for FFP and platelets
It is well recognized that patients receiving massive RBC
transfusion should also be given FFP, platelets, fibrinogen
concentrate or cryoprecipitate. However, there are no uni-
versally accepted guidelines for the replacement of these
haemostatic components. Current recommendations are
usually based on experts’ opinions or personal experience
rather than evidence from randomized controlled trials.
Two different approaches to blood component replace-
ment have been recommended and each has advantages and
disadvantages. The first approach is to transfuse FFP and
platelets prophylactically after a certain number of units of
RBCs have been transfused.27 42 However, there is no con-
sensus on the optimal ratios; these vary widely, ranging from
1:10 to 2:3 for FFP:RBCs and from 6:10 to 12:10 for pla-
telets:RBCs.27 42 43 More importantly, there is no conclusive
evidence that such a practice prevents the development of
coagulopathy or improves bleeding.64 82 There is no appar-
ent relationship between bleeding and the total volume of
plasma transfused.82 The benefit of prophylactic platelet
transfusion is also inconclusive, despite the fact that throm-
bocytopenia is commonly seen in patients who have
received massive RBC transfusion.38 40 85 Many studies
have shown that thrombocytopenia does not always correl-
ate with abnormal bleeding.17 39 82 It is plausible that both
platelet function and platelet count are fundamental for
effective haemostasis.
The second approach is to transfuse FFP, platelets or
cryoprecipitate only when there is clinical or laboratory
evidence of coagulopathy.25 37 42 86 98 For instance, when
there is microvascular bleeding, a PT or aPTT >1.5 times
normal value, thrombocytopenia with a platelet count <50–
100·109 litre1 or fibrinogen concentration <1 g litre1
(Fig. 4).1 14 25 27 64 The guidelines for blood component ther-
apy recommended by the American Society of Anesthesi-
ology Task Force on Blood Component Therapy are
summarized in Table 2.1 This approach also has its short-
comings. Clinical evidence of coagulopathy such as
microvascular bleeding at an occult site can be difficult to
Crystalloids
Colloids
RBC
FFP/PCC
Fg
Plt
Blood volume replacement
0 0.5 1.0 1.5 2.0 2.5
Hct=21–24%
PT, aPTT>1.5xnormal
Fg=1.0 g litre–1
Plt<50x109 litre–1
Fig 4 Fluid and blood component treatment in major bleeding (modified
from reference 25, with permission from European Society of Haemapher-
esis). Values of various parameters represent trigger points at which rel-
evant blood components should be transfused. RBC, red blood cells; FFP,
fresh frozen plasma; PCC, prothrombin complex concentrate; Fg, fibrino-
gen; Plt, platelets; Hct, haematocrit; PT, prothrombin time; aPTT, activated
partial thromboplastin time.
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observe.27 In addition, laboratory tests may take 30–60 min
from blood sampling to availability of results. The haemo-
static status of trauma patients with massive bleeding can
change rapidly, and hence the results might not reflect the
patient’s current status. Moreover, as discussed earlier, tests
which are carried out at a standard temperature of 37C, may
not detect hypothermia-related coagulopathy. There may be
a further delay between receiving the clinical or laboratory
evidence and the required blood components being
available, during which the coagulation status may have
changed again.
Limitations on restoration of haemostasis
Both FFP and cryoprecipitate contain coagulation factors
only in their physiological, low concentrations, which
vary between donors. During the preparation of FFP, the
levels of coagulation factors are diluted by approximately
15% in the first step as a result of the added anticoagulant
solution. Further losses might also occur during the
freezing–thawing process. Consequently, large volumes of
FFP are needed to correct coagulation factor deficiency.13
The loss of platelets during the preparation process is
more substantial: around 50% of the original number present
in whole blood.7 During storage, platelets undergo changes
which result in the loss of their functional activity.95 Hence,
even transfusion of RBCs, FFP and platelets in a 1:1:1 ratio
will not necessarily reconstitute the levels and functions of
coagulation factors and platelets to the levels seen in normal
whole blood.
The use of fresh whole blood
The use of ‘fresh’ (<24 h old) unrefrigerated whole blood
instead of RBCs in trauma patients requiring massive trans-
fusion has been proposed as means of overcoming coagu-
lopathy.26 33 This approach poses major logistic problems.
Most blood banks process almost all whole blood units into
blood components, and in an emergency situation fresh
whole blood, especially in large amounts, is therefore not
readily available. Moreover, as several countries have
implemented universal leucodepletion, i.e. all blood units
are leucodepleted before storage, whole blood which is leu-
codepleted is not really ‘whole’ as almost all platelets and
some clotting factors are removed during the leucocyte fil-
tration process.59 Hence, the use of fresh whole blood may
not correct massive transfusion-related coagulopathy and is
a rather impractical option. Moreover, the use of fresh whole
blood would preclude adequate screening testing, which
would dramatically decrease the safety of blood transfusion.
Clearly, the current practice of component replacement
therapy in trauma patients with life-threatening bleeding is
not ideal. Evidence from randomized controlled trials for a
conclusive, optimal strategy is still lacking. Nevertheless, it
may not be feasible to carry out such trials for ethical and
logistic reasons. There is a limit on what can be achieved by
blood component replacement therapy in trauma patients
with uncontrollable bleeding.
Effect of RBC transfusion on longer-term
outcome in trauma
Over the years, the risk of transfusion-transmitted infections
caused by known pathogens, such as hepatitis B, hepatitis C
and human immunodeficiency virus (HIV), has been signi-
ficantly decreased.6 However, there remains a residual risk
of infection caused by these pathogens. There is increasing
concern over infection caused by emerging pathogens, such
as the agent of variant Creutzfeldt–Jacob disease (vCJD),
hepatitis G virus, and West Nile virus.6 83 In addition, blood
transfusion is associated with a number of acute and delayed
non-infectious complications (Table 3).3
In patients with major trauma, there appears to be a rela-
tionship between RBC transfusion and poorer outcome, in
particular the development of post-injury multiple organ
failure and infection, which will be discussed in more detail.
Multiple organ failure
Multiple organ failure is a serious post-injury complication
resulting in prolonged intensive care unit (ICU) stay,
requirement for mechanical ventilation for a longer period,
and high mortality. Once MOF has developed, the mortality
rate can be as high as 36%.73 RBC transfusion has been
shown to be an independent risk factor for post-injury
MOF73 92 and there is a strong dose–response relationship
between early RBC transfusion and the development of
MOF.73 Analysis of a database consisting of 513 patients
with major trauma, severe bleeding and haemorrhagic shock
indicated that patients who developed MOF received an
average of 13 units of RBCs in the first 12 h after injury
compared with 3.8 units in patients who did not develop
MOF.73 Moreover, the age of transfused RBC has been
shown to be an independent risk factor for post-injury
MOF.107 A decrease in the volume of RBCs transfused
may decrease the risk and severity of MOF.
The precise mechanism of RBC transfusion-related MOF
is yet to be established. Nevertheless, recent evidence sup-
ports the hypothesis that, during storage, bioreactive lipids,
which have polymorphonuclear cell priming activity, are
generated from RBCs.96 While the initial insult caused by
tissue damage and hypoxia primes the inflammatory system,
Table 2 Guidelines for replacement therapy in patients with coagulopathy
Coagulation parameter Recommended therapy
Prothrombin time >1.5 times normal Fresh frozen plasma,
prothrombin complex
concentrate
Activated partial thromboplastin time
>1.5 times normal
Fresh frozen plasma
Fibrinogen <1.0 g litre1 Fibrinogen concentrate,
cryoprecipitate
Platelets <50 · 109 litre1 Platelets
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subsequent transfusion of stored RBCs containing these
bioreactive lipids activates a systemic inflammatory
response resulting in MOF.73
Post-injury infection
Infection is a common complication in trauma patients. RBC
transfusion has been shown to be an independent risk factor
for the development of post-injury infection,15 22 and several
mechanisms have been proposed. The exposure of patients
to large amounts of foreign antigens may lead to down-
regulation of the immune system.101 The presence of leu-
cocytes in RBC units has been thought to be a major
contributory factor to the immunosuppressive effect of
allogeneic blood transfusion.9 10 Nevertheless, results
from clinical trials are inconclusive as to whether leucode-
pletion eliminates the immunosuppressive effect of allogen-
eic blood.80 101 An alternative non-immune-mediated
mechanism of post-injury infection has been proposed.
Stored RBCs are less deformable and more rigid, and
once transfused they may obstruct capillary blood flow,
predisposing tissue to ischaemia and infection as well as
poor delivery of prophylactic antibiotics.63 80 101
A prospective observational study by Claridge and col-
leagues15 revealed that the infection rate in trauma patients
receiving at least one unit of RBCs during the first 48 h of
hospital admission was significantly higher than that in the
patients receiving none (33.0 vs 7.6%, P<0.0001), and there
was a strong dose-dependent correlation between the
amount transfused and the development of infection. How-
ever, the odds ratio of RBC transfusion as a risk factor for the
development of post-injury infection was only 1.084 (95%
confidence interval 1.028–1.142, P=0.0028).
In a prospective observational study, Malone and col-
leagues62 analysed data from 15 534 trauma patients, of
whom 1703 received RBC transfusion with a mean of
6.8–6.7 units. The results showed that, after controlling for
severity of shock, RBC transfusion within the first 24 h was
associated with increased mortality, admission to the ICU and
lengths of ICU and hospital stays, which may be related to an
increased risk of nosocomial infection. Nonetheless, there
was no supportive evidence for a cause–effect relationship.
The development of infection might be associated with
the length of storage of transfused RBCs. Based on
269 patients undergoing coronary artery bypass graft sur-
gery, Vamvakas and Carven102 found that the risk of post-
operative pneumonia increased by 1% per day of increase in
the mean storage time of the transfused RBC. In addition, a
similar finding was observed by Leal-Noval and col-
leagues,57 who conducted a study in 897 patients undergoing
cardiac surgery. The results showed that each day of storage
of the oldest unit increased the risk of pneumonia by 6% and
transfusion of RBC units that were stored for >28 days could
be a risk factor for nosocomial pneumonia.
It is noteworthy that studies on the effect of RBC trans-
fusion on post-injury infection are mainly observational
studies and should be interpreted with caution. Such studies
cannot clearly define whether RBC transfusion causes post-
injury complications or whether trauma patients who require
RBC transfusion have had more severe illnesses, and, there-
fore, are more likely to develop complications. Only ran-
domized prospective trials will provide a definitive answer.
However, conducting such trials in severe trauma patients is
extremely difficult, if not impossible, as exemplified by
Schulman and colleagues.93 94 They conducted a random-
ized prospective trial to establish the effect of varying age of
RBCs on clinical outcome in trauma patients. Patients were
only to be randomized if there were at least 15 units of
‘young’ (<11 days old) and 15 units of ‘old’ (>20 days
old) type-specific leucodepleted RBCs available at the
time. Despite 8000 injuries being evaluated, of which
3600 were severe, only 24 patients could be randomized
and included in the trial, due to the limitation of blood
bank inventory. On average, patients included in the trial
received 10 units of RBCs. There were no statistically sig-
nificant differences in post-injury complications between the
two groups, which could be due, at least partly, to the limited
number of patients studied. However, it is also possible that
not only the age of RBCs, but also other factors, contribute to
transfusion-associated post-injury infection.
RBC units have a limited shelf-life of around 42 days.
Blood banks usually issue the oldest units of RBCs to avoid
wastage from expired units. It may seem logical to suggest
that fresher RBC units be used for resuscitation of trauma
patients with massive blood loss. However, this approach
might not be practical in terms of inventory management. A
more practical strategy would be to attempt to reduce the
amount of RBCs transfused. A prospective randomized con-
trolled trial in critically ill trauma patients (Transfusion
Requirements in Critical Care Trial, TRICC) has shown
that a restrictive RBC transfusion strategy (haemoglobin
concentration 70 g litre1) appears to be safe.41 67
The need for haemostatic agents
Despite significant improvements in resuscitation of trauma
patients with haemorrhagic shock, coagulopathy-related
bleeding remains a major challenge. The mainstay of
Table 3 Transfusion-associated non-infectious complications of massive
transfusion
Acute (within 24 h of transfusion)
Haemolytic reactions
Febrile non-haemolytic reactions
Allergic reactions
Transfusion-related acute lung injury
Hypothermia
Hypocalcaemia
Metabolic acidosis
Delayed (>24 h after transfusion)
Alloimmunization
Immunosuppression
Post-transfusion purpura
Graft-vs-host disease
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coagulopathy management is transfusion of FFP, platelets,
fibrinogen and cryoprecipitate where available. During the
preparation and storage of blood components, platelets
undergo changes which result in progressive loss of their
viability and function. Although some of the changes are
reversible, there is little evidence that transfused platelets
resume their normal function immediately, and the func-
tional activities of coagulation factors in FFP are also
decreased from their original level. Despite these storage
changes, FFP, platelets and cryoprecipitate provide suffi-
cient haemostasis in most patients. However, in certain
cases, such as when coagulopathy is present in conjunction
with hypothermia and acidosis, there is a limit on the level of
haemostasis that can be restored by replacement therapy. In
some cases, even adequate replacement fails to control the
life-threatening bleeding resulting in exsanguination.
Alternative haemostatic treatments, which are efficacious
in such a setting, might be life-saving, and the use of hae-
mostatic treatments that reduce RBC transfusion require-
ment might decrease post-injury complications such as
MOF and infection, and eventually improve outcome.
The precise cause of coagulopathy-related bleeding can
be difficult to identify and is usually multifactorial. An ideal
haemostatic agent should therefore be efficacious in a wide
range of haemostatic dysfunctions, simple to store and use,
and have a rapid action. In addition, as the haemostatic status
of patients with severe trauma may quickly swing from
bleeding to thrombosis,31 56 97 a relatively short half-life is
necessary to minimize thromboembolic complications.
Activated recombinant coagulation factor VII (rFVIIa) is
a potential candidate. A recent review by Goodnough and
colleagues32 has shown that rFVIIa may provide effective
haemostasis in a wide range of bleeding conditions. In
trauma patients with coagulopathic bleeding, Dutton and
colleagues20 used rFVIIa as the last resort and found that
the bleeding decreased in most cases. A randomized con-
trolled trial showed that rFVIIa significantly decreased the
RBC transfusion requirement in patients with major trauma,
and there were trends towards the reduction of MOF and
acute respiratory distress syndrome.11 Detailed results are
yet to be published. Nonetheless, based on the results from
36 patients with severe trauma, the Israeli Multidisciplinary
rFVIIa Task Force issued guidelines for the use of rFVIIa in
uncontrolled bleeding,66 which recommended that optimal
preconditions (fibrinogen concentration >0.5 g litre1,
platelet count >50 litre1, pH >7.2) should be achieved
before the administration of rFVIIa. As with any haemo-
static agent, there are concerns over the potential thrombo-
genicity of rFVIIa.5 Nevertheless, there are some clinical
data showing a favourable safety and efficacy profile.89
Conclusions
Over recent years, the resuscitation of trauma patients
with haemorrhagic shock has improved progressively.
Nevertheless, non-surgically correctable bleeding remains
a major challenge. Currently, blood component replacement
therapy remains the mainstay of coagulopathy-related bleed-
ing. In certain cases, this might fail to control the bleeding
resulting in exsanguination. Although RBC transfusion can
be life-saving, its negative effects on post-injury outcome
have been well documented. Haemostatic agents, which can
effectively control bleeding and reduce the amount of RBCs
required, may decrease mortality and morbidity in trauma
patients but are unlikely to replace blood transfusion
completely.
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